Physical Activity on Prescription for Children With Obesity (IMPA)

December 21, 2023 updated by: Susanne Bernhardsson, Vastra Gotaland Region

Implementation of Physical Activity on Prescription for Children With Obesity in Paediatric Health Care (IMPA): a Feasibility Study

Background: physical inactivity is a main cause of childhood obesity. Physical activity on prescription (PAP) is an evidence-based intervention for adults, but has not been evaluated in children with obesity.

Aim: to evaluate the feasibility of a PAP intervention for children with obesity by assessing both clinical patient outcomes and implementation outcomes.

Method: a single-arm clinical trial in which children with obesity participate in a 4-month PAP intervention. Measurement points are baseline and 4 months, with long-term follow-ups at 8 and 12 months.

Population: children with obesity.

Intervention: physical activity on prescription (PAP).

Patient outcomes: physical activity level/pattern (including sedentary time), BMI, waist circumference, metabolic risk markers, health-related quality of life, self-efficacy for physical activity, motivation for physical activity.

Implementation outcomes: coherence, cognitive participation, collective action, and reflexive monitoring in relation to PAP (the four core constructs of the Normalization Process Theory); appropriateness, acceptability and feasibility of PAP; barriers and facilitators for implementing PAP; recruitment and attrition rates, and intervention fidelity and adherence.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Physical inactivity is a main cause of childhood obesity which tracks into adulthood obesity, making it important to address early in life. Physical activity on prescription (PAP) is an evidence-based intervention developed in Sweden that has shown good effect on physical activity levels in adults, but has not been evaluated in children with obesity. This clinical study is nested in a larger research project aiming to assess the prerequisites, determinants, and feasibility of implementing PAP adapted to children with obesity in paediatric health care. Children's and parents' experiences of participating in the PAP intervention will also be explored.

In a first, pre-clinical trial, phase, healthcare providers and managers from 26 paediatric clinics in Region Västra Götaland, Sweden, will participate in a web-based survey, and a subset of this sample in a focus group study. Findings from these two data collections will form the basis for further development and adaptation of PAP to the target group and context.

In the project's second phase, this adapted PAP intervention will be evaluated in a clinical study in a sample of approximately 60 children with obesity, between 6 and 12 years of age, and one of their parents/legal guardians. Clinical and implementation outcomes will be assessed pre- and post-intervention, and at 8 and 12 months' follow-up. Clinical outcomes are physical activity level/pattern, BMI, waist circumference, metabolic risk markers (blood pressure, fasting plasma glucose, high- and low-density lipoprotein cholesterol, insulin resistance, and triglycerides), quality of life, self-efficacy and motivation for physical activity, and intervention satisfaction. Implementation outcomes are the four core constructs of the Normalization Process Theory; coherence, cognitive participation, collective action, and reflexive monitoring; appropriateness, acceptability and feasibility of the PAP intervention; barriers and facilitators for implementing PAP; recruitment and attrition rates, and intervention fidelity and adherence.

The clinical study is nested in a larger research project employing a hybrid implementation-effectiveness design. Design and analysis of the included studies is guided by the Normalization Process Theory.

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Gothenburg, Sweden
        • Recruiting
        • Regionhälsan, Region Västra Götaland
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 12 years (Child)

Accepts Healthy Volunteers

No

Description

Pre-trial phase/healthcare practitioner:

Inclusion criteria:

- being a healthcare practitioner or manager involved in the treatment of children with obesity at a paediatric healthcare clinic in Region Västra Götaland

Clinical trial/patients:

Inclusion criteria:

  • aged 6-12 years
  • diagnosed with obesity (age adjusted BMI>ISO-BMI 30)
  • having an insufficient physical activity level according to national recommendations
  • being willing to participate and perform the chosen activity/-ies
  • having a parent who is willing to participate.

Exclusion criteria:

  • severe psychiatric comorbidity
  • severe intellectual or physical disability

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Physical activity on prescription
Physical activity on prescription is a behaviour change intervention comprising 3 components: a person-centred pre-intervention dialogue, a written prescription for individually tailored physical activity, and a structured follow-up.
The intervention in this study will comprise the 3 PAP components. Participants will take part in all components and perform one or several physical activities of their choice in accordance to the written prescription, at the prescribed frequency and duration, for a period of 4 months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in physical activity level
Time Frame: 4, 8, 12 months after baseline
Change in time spent in moderate to vigorous physical activity, measured with accelerometry
4, 8, 12 months after baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in physical activity pattern
Time Frame: 4, 8, 12 months after baseline
Change in sedentary time, time spent in low, moderate and vigorous physical activity, measured with accelerometry
4, 8, 12 months after baseline
Change in BMI
Time Frame: 4, 8, 12 months after baseline
Change in age- and sex adjusted BMI (measured as weight and height combined to BMI). This outcome will also be measured as BMI Standard deviation score (SDS)
4, 8, 12 months after baseline
Change in health-related quality of life
Time Frame: 4, 8, 12 months after baseline
Change in self-reported health-related quality of life, measured with KIDSCREEN-10
4, 8, 12 months after baseline
Change in self-efficacy for physical activity
Time Frame: 4, 8, 12 months after baseline
Change in perceived self-efficacy for physical activity, measured with the Self-efficacy for physical activity questionnaire
4, 8, 12 months after baseline
Change in motivation for physical activity
Time Frame: 4, 8, 12 months after baseline
Change in perceived motivation for physical activity, measured with the Motivation for physical activity questionnaire
4, 8, 12 months after baseline
Intervention acceptability
Time Frame: Post-intervention at 4 months
Intervention acceptability will be measured with the Client Satisfaction Questionnaire (CSQ-8)
Post-intervention at 4 months
Change in systolic and diastolic blood pressure
Time Frame: Baseline to 12 months
Both systolic and diastolic blood pressure will be measured in mmHg
Baseline to 12 months
Change in fasting plasma glucose
Time Frame: Baseline to 12 months
Change in fasting plasma glucose will be measured in mmol/litre
Baseline to 12 months
Change in Hemoglobin A1C (HbA1C)
Time Frame: Baseline to 12 months
Change in HbA1C will be measured in mmol/litre
Baseline to 12 months
Change in high- and low-density lipoprotein cholesterol
Time Frame: Baseline to 12 months
Change in high- and low-density lipoprotein cholesterol will be measured in mmol/litre
Baseline to 12 months
Change in fasting P-insulin
Time Frame: Baseline to 12 months
Change in fasting P-insulin will be measured in mIE/litre
Baseline to 12 months
Change in triglycerides
Time Frame: Baseline to 12 months
Change in triglycerides will be measured in mmol/litre
Baseline to 12 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in healthcare practitioners' attitudes towards PAP in relation to the four core constructs of the NPT: coherence, cognitive participation, collective action, and reflexive monitoring
Time Frame: Pre-implementation to post-intervention at 4 months, and long-term follow-up at 12 months
Coherence, cognitive participation, collective action, and reflexive monitoring will be assessed using the Swedish version of Normalization MeAsure Development (S-NoMAD)
Pre-implementation to post-intervention at 4 months, and long-term follow-up at 12 months
Change in healthcare practitioners' acceptability of the PAP intervention
Time Frame: Pre-implementation to post-intervention at 4 months, and long-term follow-up at 12 months
Acceptability of PAP will be assessed using the Acceptability of Intervention Measure (AIM)
Pre-implementation to post-intervention at 4 months, and long-term follow-up at 12 months
Change in healthcare practitioners' appropriateness of the PAP intervention
Time Frame: Pre-implementation to post-intervention at 4 months, and long-term follow-up at 12 months
Appropriateness of PAP will be assessed using the Intervention Appropriateness Measure (IAM)
Pre-implementation to post-intervention at 4 months, and long-term follow-up at 12 months
Change in healthcare practitioners' feasibility of the PAP intervention
Time Frame: Pre-implementation to post-intervention at 4 months, and long-term follow-up at 12 months
Feasibility of PAP will be assessed using the Feasibility of Intervention Measure (FIM)
Pre-implementation to post-intervention at 4 months, and long-term follow-up at 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Susanne Bernhardsson, Assoc. Prof., Vastra Gotaland Region

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 7, 2022

Primary Completion (Estimated)

May 31, 2024

Study Completion (Estimated)

May 31, 2025

Study Registration Dates

First Submitted

March 29, 2021

First Submitted That Met QC Criteria

April 13, 2021

First Posted (Actual)

April 19, 2021

Study Record Updates

Last Update Posted (Actual)

December 26, 2023

Last Update Submitted That Met QC Criteria

December 21, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 2020-01244

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

IPD will be shared upon reasonable request

IPD Sharing Time Frame

After completion of the study and publication of study results

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity, Childhood

Clinical Trials on Physical activity on prescription (PAP)

3
Subscribe